Biopharma | January 07, 2026
Medera doses final patient in high-dose HFpEF gene therapy trial
Heart failure affects an estimated 64.3 million people worldwide
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
India’s pharmaceutical sector stands at a pivotal inflection point
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
